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Taken together, venous and arterial thromboembolism form the commonest causes of death, admission to hospital, and physical disability in the second half of life. Their incidence, prevalence, and mortality all increase steeply with age. The mechanisms are not known but may include changes related to age, such as increased concentrations of clotting factors,' increased activation of coagulation and platelets,2 decreased fibrinolytic activity,' increased immobility and venous stasis in the case of venous thrombosis, increased atherosclerosis in the case of arterial thrombosis, and increased frequency of atrial fibrillation in the case of arterial embolism.
As fibrin is an important component of both venous and arterial thrombi and emboli, anticoagulant drugs, which reduce the formation of fibrin, should be effective in prevention and treatment. Although heparin and oral anticoagulant drugs have been used for over 40 years, proof has been slow in coming owing to the historical inability of doctors to perform adequately controlled trials,' as with many other treatments. Evidence is, however, increasing that anticoagulant drugs are indeed effective in preventing both venous and arterial thromboembolism, thereby reducing both morbidity and mortality.' [3] [4] [5] [6] [7] [8] [9] [10] [11] Low doses of anticoagulant treatment in preventing venous thromboembolism
The prevention of venous thromboembolism in elderly patients is important not only because of their high risk but also because of the increased difficulty in diagnosing pulmonary embolism before death. Fewer than 10% of patients aged over 70 with fatal pulmonary Effect on venous thromboembolism and mortality ofprophylactic low doses ofheparin (5000 units every eight to and heparins of low molecular weight. '3 In patients who are not having operations low doses of heparin significantly reduced the incidence of deep vein thrombosis after myocardial infarction, stroke, heart failure, and chest infection.6 A large controlled study of patients with short term illness admitted to general medical wards (of whom over 43% were aged over 70) found that low doses of heparin significantly reduced mortality, according to the principle of"intention to treat" (see table) . 7 The reduction in mortality was apparent in all age groups, and only one major bleed was reported. Patients with suspected myocardial infarction and stroke were excluded from this study. In a randomised study of elderly patients with acute stroke (mean age 76) low doses of heparin significantly reduced venous thromboembolism and mortality (see table) . 8 The reduced mortality seemed greater in patients with less severe strokes and was not offset by increased bleeding or by increased mortality when patients with pulmonary embolism were excluded. Computed tomography was not performed in this study to exclude the 10% of patients with haemorrhagic stroke. 
These data support the recommendations of the National Institutes of Health consensus development conference that both medical and surgical patients over the age of 40 be given low doses of heparin routinely during their acute immobility to prevent venous thromboembolism unless there are contraindications.9 Old age is not a contraindication: it is a positive indication as the higher risk should confer a greater cost benefit and reduction in risk.
Full doses of anticoagulant drugs in treating venous and arterial thromboembolism Venous thromboembolism -Established venous thromboembolism is largely preventable by low doses of heparin but is still a common problem for physicians and surgeons who neglect prophylaxis, especially in elderly patients in whom diagnosis is more difficult.'2 As in younger patients clinical diagnosis is unreliable and should be confirmed by objective methods.'0 Controlled or randomised trials of anticoagulant treatment have been slow in coming, but the overall evidence from recent trials suggests that treatment with heparin and warfarin reduces recurrent thromboembolism.'0 As with preventive studies the mean age of patients in these trials was high: no evidence was found that anticoagulant drugs were less effective in older patients.
Myocardial infarction -The overall evidence suggests that anticoagulant treatment reduces mortality after myocardial infarction by about a fifth in the short term and long term. ' In trials in which anticoagulant drugs were properly controlled long term oral anticoagulant treatment reduced mortality by about half. 'I The Dutch sixty plus study showed that older patients who were already stable taking oral anticoagulant drugs after myocardial infarction did better if they continued taking them.'67 Although physicians may prefer long term prophylaxis with aspirin,'8 they should still consider short term anticoagulant treatment to prevent venous thrombosis or recurrent coronary thrombosis after thrombolytic treatment. ' Cardiac thromboembolism, stroke, and peripheral arterial disease-No adequate controlled trials have been reported in patients with cardiac thromboembolism, stroke, and peripheral arterial disease until recently. '9 Anticoagulant treatment after cardioembolic stroke seems to be safe in selected patients (particularly when haemorrhage is excluded by computed tomography20); a European collaborative study of oral anticoagulant drugs versus aspirin or placebo in patients with atrial fibrillation and previous stroke is in progress. 20 The reduction in mortality from stroke by low doses of heparin has been noted.8 A recent randomised controlled trial of oral anticoagulants in patients having femoropopliteal grafting for peripheral arterial disease (of whom 42% were aged over 65) showed significant reduction in mortality." Further studies of anticoagulants in preventing recurrent arterial thrombosis are required and should include as many elderly patients as possible because they are most at risk.
Risk of bleeding-Although some early studies reported a higher risk of bleeding in older patients given therapeutic intravenous heparin, this was given before the routine use of standardised laboratory monitoring. In a recent large study of 2656 patients bleeding associated with heparin treatment was not significantly associated with age.2' Similarly, the largest reported experience of bleeding associated with long term anticoagulant treatment showed no correlation with age.'5 The risks of bleeding are reduced by Computed tomogram showing left sided internal capsule haematoma in a patient with right sided hemiparetic stroke observing contraindications, by giving heparin by continuous infusion rather than as a bolus injection, by standardised monitoring of both heparin and warfarin, by replacing heparin early with oral anticoagulant drugs, and by adopting lower therapeutic ranges for control by oral anticoagulants.'0'5 Age alone is not a contraindication to full dose anticoagulation. It is sensible to recognise that sensitivity to warfarin (receptor affinity) increases with age, requiring a lower dose22; that the diseases and drugs which may increase the risks of bleeding are more common in the elderly; and that mental impairment may reduce compliance. Such problems are not, however, confined to the elderly: they also apply to younger alcoholics,2 who form an equally large proportion ofmy general medical patients in Glasgow.
Conclusion
Anticoagulant drugs reduce the morbidity and mortality from venous and arterial thrombotic disease, especially in older patients who have the highest risk. These benefits are not offset by an increased risk of bleeding. 
ANY QUESTIONS
How effective is laser endarterectomy, and how widely used is the technique?
Lasers have been used in arterial surgery experimentally and in clinical practice, principally in techniques with microvascular anastomosis and recanalisation of atherosclerotic vessels. In microvascular anastomosis spot welds can be made joining small vessels of 1 mm or less in diameter or by coagulating collagen or blood around the weld to act as a support.
With blocked arteries in arteriosclerosis it has been shown that atherosclerotic plaque can be vaporised with various lasers, a technique that is especially effective when the plaque is mainly composed of cholesterol. Calcified plaque is more difficult to remove. The technique differs from endarterectomy, when plaque and occluding thrombus are removed surgically.
Several clinical studies have been made using neodymium yttrium aluminium garnet (YAG) or argon lasers to recanalise occluded femoral arteries. The failure rate seems higher than that of surgical methods either because of failure to vaporise calcified plaque or because of immediate thrombosis. Perforation of the artery is the main complication; the effect of vaporised plaque debris on the peripheral vascular bed seems to be minimal but may depend on the quantity of plaque treated.
So far the results do not compare favourably with established methods of treatment by surgery or, indeed, by balloon angioplasty. There may, however, be a place for a combination of percutaneous laser treatment with balloon angioplasty, with the obvious advantage that patients do not need to have surgery. 
